Pouruchis Bhiwandiwalla
Gynecology · Raleigh, NCNPI 1376576967
Payments from drug & device makers
Across 525 payments — averaging $4310.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$815K
- Mylan Inc.$479K
- Organon$389K
- AbbVie$166K
- Medicines360$113K
- Evofem Biosciences, Inc.$76K
- plus $224K from 18 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$123,47578%
- Travel & lodging$28,74918%
- Food & beverage$4,8533%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 45 | $815,345 |
| Mylan Inc. | 48 | $479,219 |
| Organon | 115 | $388,949 |
| AbbVie | 168 | $166,183 |
| Medicines360 | 13 | $112,674 |
| Evofem Biosciences, Inc. | 33 | $76,249 |
| Bayer | 33 | $57,583 |
| AMAG Pharmaceuticals, Inc. | 6 | $49,441 |
| Myovant Sciences GmbH | 7 | $27,518 |
| Sumitomo Pharma America, Inc. | 13 | $26,341 |
| Mylan Technologies Inc. | 5 | $22,376 |
| GSK | 2 | $13,700 |
| Exeltis, USA Inc. | 7 | $9,028 |
| Urovant Sciences Inc | 1 | $6,000 |
| Astellas Pharma US Inc | 4 | $5,381 |
| Myovant Sciences Inc. | 4 | $5,120 |
| Paratek Pharmaceuticals, Inc. | 1 | $1,200 |
| Scynexis, Inc. | 2 | $301 |
| Mayne Pharma Commercial LLC | 9 | $256 |
| Lupin Inc. | 1 | $26 |
| Duchesnay USA Incorporated | 1 | $16 |
| Pfizer | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
| Unified Women's Healthcare, LP | 5 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orilissa$124,868
- ORIAHNN$42,640
- Veozah$5,266
- SELECT-OB PLUS DHA$615
- Slynd$615
- NEXTSTELLIS$124
- Skyrizi$101
How this compares
$2,262,934 in reported general payments places this provider in the 95th percentile of 90 gynecology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 17 | $8,131 |
| Estradiol | 16 | $1,264 |
| ValacyclovirValacyclovir Hcl | 15 | $646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $15 | $8,13117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 gynecology providers in North Carolina.
Other gynecology in Raleigh
- Jerome GardnerRaleigh$101K
- Lisa RobertsRaleigh$6K
- Marianna LawRaleigh$3K
- James CarrRaleigh$3K
- Rosemarie NewmanRaleigh$3K
- Andrea TorsoneRaleigh$1K
- Suzanne KaminskiRaleigh$719
- Elizabeth Roede BarbeeRaleigh$622
- Lorena BenavidesRaleigh$513
- Sarah MoustafaRaleigh$399
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.